Griffith University’s Institute for Glycomics has partnered with Hong Kong listed China Grand Pharma’s newly established Australian company Grand Medical Ltd to develop a new drug for Human Parainfluenza Virus. Human parainfluenza virus (hPIV) commonly causes upper and lower respiratory illnesses in infants, young children, the elderly, and people with weakened immune systems, including transplant […]